The benefits of nonsteroidal mineralocorticoid receptor antagonists remain intact in patients with CKD and T2DM, despite the use of other protective medications, such as sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide-1 receptor agonists [23, 24]. The gene discussed is NR3C2; the disease is chronic kidney disease.